Gripostad forte

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT HRIPOCYTRON FITO

Composition:

Active substance: 1 tablet contains chlorophyllipt extract, thick (10.76:1) (extraction agent ethanol 93%) – 12.5 mg or 25 mg;

Excipients: sugar, ascorbic acid, calcium stearate.

Pharmaceutical form. Tablets.

Main physicochemical properties: tablets from light green to green in color with speckles, flat cylindrical in shape, with a score line and bevel, with a specific odor.

Pharmacotherapeutic group. Preparations used for throat diseases. Antiseptics. ATC code R02A A20.

Pharmacological Properties.

Pharmacodynamics.

Chlorophyllipt is a mixture of chlorophylls derived from eucalyptus leaves. The drug exerts antibacterial (bacteriostatic and bactericidal) effects against staphylococci, as well as antiseptic and anti-inflammatory actions.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications. Diseases of the upper respiratory tract (tonsillitis, pharyngitis, laryngitis), as well as aphthous and ulcerative stomatitis.

Contraindications. Hypersensitivity to chlorophyllipt or to other components of the drug.

Interaction with other medicinal products and other forms of interaction. Enhances the effect of antiseptic agents.

Special precautions.

Before starting use, consult a physician.

After the first application, a pause of 6–8 hours should be made. Course treatment with the drug is possible only after confirming the absence of an allergic reaction to the concentrated chlorophyllipt extract (possible swelling of the lips, nasal mucosa, pharynx, and other allergic reactions). If any of the above symptoms occur, discontinue use of the drug and consult a physician.

If a patient has known intolerance to certain sugars, medical advice should be sought before taking this medicinal product.

Use during pregnancy or breastfeeding. Safety and efficacy of the drug during pregnancy or breastfeeding have not been studied; therefore, the drug should not be used in these patient groups.

Ability to affect reaction rate when driving or operating machinery. Not studied.

Dosage and Administration.

For adults, tablets of 12.5 mg or 25 mg should be prescribed depending on the severity of the pathological process. The tablet must not be swallowed or chewed, but held in the mouth until completely dissolved. The daily dose for adults is 25 mg taken 5 times per day. Frequency of administration: 1 tablet (12.5 mg or 25 mg) every 4–5 hours. Treatment course: 7 days.

Children. There is no experience with the use of the drug in children.

Overdose. May result in an intensification of adverse reactions.

Side effects.

Immune system disorders: allergic reactions, including rash, itching, angioedema, hyperemia.

Gastrointestinal disorders: irritation of the oral mucosa, nausea, vomiting.

Nervous system disorders: headache, dizziness.

Shelf life: 3 years.

Storage conditions. Store at a temperature not exceeding 25 °C in the original packaging.

Keep out of reach of children.

Packaging.

Tablets No. 20, No. 10x2 in blisters in a carton.

Classification for supply. Over-the-counter (without prescription).

Manufacturer.

Limited Liability Company "Research Plant "GNCLS".

Limited Liability Company "Pharmaceutical Company "Zdorovya".

Manufacturer's location and address of business activity.

Ukraine, 61057, Kharkiv region, city of Kharkiv, Vorobiova Street, building 8.

(Limited Liability Company "Research Plant "GNCLS")

Ukraine, 61013, Kharkiv region, city of Kharkiv, Shevchenko Street, building 22.

(Limited Liability Company "Pharmaceutical Company "Zdorovya")